{
    "clinical_study": {
        "@rank": "45122", 
        "arm_group": {
            "arm_group_label": "Autologous Protein Solution \"APS(TM)\"", 
            "description": "Patients who have been treated with a single, intra-articular injection."
        }, 
        "brief_summary": {
            "textblock": "This prospective single-center study will evaluate the safety and tolerability of a single\n      dose of \"APS(TM)\" treated patients with OA of the knee who have failed conservative OA\n      therapy. The study will also evaluate efficacy by assessing patient pain and functionality."
        }, 
        "brief_title": "Evaluation of Intra-articular Injection of Autologous Protein Solution (\"APS(TM)\") for the Treatment of Osteoarthritis (OA)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gonarthrosis", 
            "Knee Osteoarthritis", 
            "Osteoarthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Eligibility Criteria:\n\n          -  Male or female \u226540 years.\n\n          -  Willingness and ability to comply with the study procedures and visit schedules and\n             ability to follow verbal and written instructions.\n\n          -  A standing radiograph of the knee showing a Kellgren grade of 2 or 3\n\n          -  Frequency of knee pain on most days over the last month.\n\n          -  Diagnosis of unilateral knee OA\n\n          -  Body mass index (BMI) \u226440 kg/m2.\n\n          -  Failed conservative OA therapy.\n\n          -  Signed an independent ethics committee (IEC)-approved informed consent form (ICF).\n\n          -  Willingness to abstain from the use of topical pain therapies, intra-articular\n             corticosteroids, and viscosupplementation during the study.\n\n          -  Willingness to abstain from systemic pain medications except rescue medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients with OA of the knee who have failed conservative OA"
            }
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773226", 
            "org_study_id": "APSS-11-00"
        }, 
        "intervention": {
            "arm_group_label": "Autologous Protein Solution \"APS(TM)\"", 
            "description": "A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins", 
            "intervention_name": "Autologous Protein Solution \"APS(TM)\"", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autologous Protein Solution", 
            "APS", 
            "Osteoarthritis", 
            "Injection"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "contact": {
                "email": "kog@st-anna.nl", 
                "last_name": "Walter van der Weegen"
            }, 
            "facility": {
                "address": {
                    "city": "Geldrop", 
                    "country": "Netherlands"
                }, 
                "name": "St. Anna Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Single-Center Clinical Study of a Single Intra-Articular Injection of Autologous Protein Solution (\"APS(TM)\") in Patients With Osteoarthritis (OA) of the Knee", 
        "overall_contact": {
            "email": "kog@st-anna.nl", 
            "last_name": "Walter van der Weegen", 
            "phone": "+31 402864864"
        }, 
        "overall_official": {
            "affiliation": "St. Anna Hospital, Geldrop, NL", 
            "last_name": "R.A.M. van Drumpt, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 months post-injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773226"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "pain, stiffness, and function", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 4, 13, 26 wks"
            }, 
            {
                "measure": "Number of patients using rescue medication", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months post-injection"
            }
        ], 
        "source": "Biomet, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biomet, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}